The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma

Pathology

Volumn 45, Issue 6, 2013, Pages 553-558

  Westaway, Darin D ^a   Toon, Christopher W ^a,b,c   Farzin, Mahtab ^b   Sioson, Loretta ^b   Watson, Nicole ^b   Brady, Peter W ^b   Marshman, David ^b   Mathur, Manu M ^b   Gill, Anthony J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c Histopath Pathology   (Australia)

Author keywords

Adenocarcinoma grading; IASLC ATS ERS; Lung adenocarcinoma

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER GRADING; CLASSIFICATION; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG ADENOCARCINOMA; LUNG TUMOR; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PRACTICE GUIDELINE; PROGNOSIS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS;

EID: 84887894876     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32836532ae     Document Type: Article

References (25)

1. Boyle P, Levin BE. World Cancer Report. Lyon: IARC Press; 2008.
2. Rusch V, Appelman H, Blackstone E, et al. AJCC Cancer Staging Manual. 7th ed. Chicago: American Joint Committee on Cancer, Springer, 2009.
3. Mountain C. Staging classification of lung cancer. A critical evaluation. Clin Chest Med 2002; 23: 103-21.
4. Shedden K, Taylor J, Enkemann S, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008; 14: 822-7.
5. Travis WD, Brambilla E, Van Schil P, et al. Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. Eur Respir J 2011; 38: 239-43.
6. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.
7. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-8.
8. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
9. Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. (Erratum appears in N Engl J Med 2011; 364: 588.) N Engl J Med 2010; 363: 1693-703.
10. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011; 17: 2081-6.
11. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
12. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-85.
13. Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011; 6: 1496-504.
14. Yokose T, Suzuki K, Nagai K, Nishiwaki Y, Sasaki S, Ochiai A. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3cm or less in diameter. Lung Cancer 2000; 29: 179-88.
15. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011; 24: 653-64.
16. Travis W, Colby T, Corrin B, et al. World Health Organization International Histological Classification of Lung Tumours. Histological Typing of Lung and Pleural Tumours. 3rd ed. Berlin: Springer-Verlag, 1999.
17. TravisW, Brambilla E, Muller-Hermelink H, et al. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. World Health Organisation Classification of Tumours. Lyon: IARC Press; 2004.
18. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008; 32: 810-27.
19. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology 2009; 54: 12-27.
20. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010; 34: 1155-62.
21. Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012; 30: 1438-46.
22. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Cassification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients. J Thorac Oncol 2013; 8: 52-61.
23. Kadota K, Suzuki K, Kachala SS, et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol 2012; 25: 1117-27.
24. von der Thusen J, Tham Y, Pattenden H, et al. Prognostic significance of predominant histologic pattern and nuclear grade in resected adenocarcinoma of the lung: potential parameters for a grading system. J Thorac Oncol 2013; 8: 37-44.
25. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in nonsmall- cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23: 857-65.